DEXI

Summary

DEXI (Dexi homolog, HGNC:13267) is a protein-coding gene on chromosome 16p13.13, encoding Dexamethasone-induced protein (O95424).

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 2 total — 1 pathogenic
• MANE Select transcript: NM_014015

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13267
Approved symbol	DEXI
Name	Dexi homolog
Location	16p13.13
Locus type	gene with protein product
Status	Approved
Aliases	MYLE
Ensembl gene	ENSG00000182108
Ensembl biotype	protein_coding
OMIM	617901
Entrez	28955

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000331808, ENST00000469379, ENST00000570440, ENST00000570992

RefSeq mRNA: 1 — MANE Select: NM_014015 NM_014015

CCDS: CCDS10545

Canonical transcript exons

ENST00000331808 — 2 exons

Exon	Start	End
ENSE00001296327	10941569	10942468
ENSE00001409665	10928891	10929559

Expression profiles

Bgee: expression breadth ubiquitous, 282 present calls, max score 97.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.0911 / max 58.9826, expressed in 1756 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
156230	10.6180	1754
156231	0.4731	239

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	97.83	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.26	gold quality
left adrenal gland cortex	UBERON:0035825	96.75	gold quality
left adrenal gland	UBERON:0001234	96.52	gold quality
gastrocnemius	UBERON:0001388	96.42	gold quality
heart left ventricle	UBERON:0002084	96.42	gold quality
cardiac ventricle	UBERON:0002082	96.26	gold quality
right adrenal gland	UBERON:0001233	96.24	gold quality
right atrium auricular region	UBERON:0006631	96.18	gold quality
muscle of leg	UBERON:0001383	96.16	gold quality
adrenal cortex	UBERON:0001235	96.05	gold quality
right adrenal gland cortex	UBERON:0035827	95.96	gold quality
cardiac atrium	UBERON:0002081	95.90	gold quality
muscle organ	UBERON:0001630	95.60	gold quality
descending thoracic aorta	UBERON:0002345	95.57	gold quality
thoracic aorta	UBERON:0001515	95.31	gold quality
ascending aorta	UBERON:0001496	95.28	gold quality
heart	UBERON:0000948	95.24	gold quality
right lobe of liver	UBERON:0001114	95.17	gold quality
adrenal gland	UBERON:0002369	95.06	gold quality
right frontal lobe	UBERON:0002810	94.92	gold quality
prefrontal cortex	UBERON:0000451	94.82	gold quality
caudate nucleus	UBERON:0001873	94.62	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.55	gold quality
lower esophagus	UBERON:0013473	94.53	gold quality
nucleus accumbens	UBERON:0001882	94.50	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	94.45	gold quality
cingulate cortex	UBERON:0003027	94.44	gold quality
putamen	UBERON:0001874	94.38	gold quality
anterior cingulate cortex	UBERON:0009835	94.38	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.05

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting DEXI, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-23A-5P	99.94	65.39	468
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-5689	99.50	71.26	1154
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669
HSA-MIR-19B-2-5P	99.36	67.07	1669
HSA-MIR-2115-3P	99.31	69.68	2026
HSA-MIR-5582-5P	99.27	71.42	1879
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-153-3P	98.96	72.51	1644
HSA-MIR-361-5P	98.95	70.16	1340
HSA-MIR-374A-3P	98.87	67.82	1531
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-1-5P	98.70	68.66	1017

Literature-anchored findings (GeneRIF, showing 5)

• Silencing of DEXI leads to drug resistance in colon cancer. (PMID:21901246)
• DEXI is an unappreciated autoimmune disease candidate gene, and illustrate the power of the 3C approach in progressing from genome-wide association studies results to candidate causal genes (PMID:21989056)
• The data indicates a possible regulatory role for multiple sclerosis-associated non-coding CLEC16A SNPs and a common control mechanism for the expression of CLEC16A, SOCS1 and DEXI. (PMID:23151489)
• Reduced DEXI mRNA level was associated with type 1 diabetes risk alleles of CLEC16A. (PMID:25008175)
• These observations support DEXI as the aetiological gene in the type 1 diabetes-associated 16p13 genomic region, and provide the first indication of a link between this candidate gene and the regulation of local antiviral immune responses in beta cells. (PMID:30478640)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	dexi	ENSDARG00000055474
mus_musculus	Dexi	ENSMUSG00000038055
rattus_norvegicus	Dexi	ENSRNOG00000091318

Protein

Protein identifiers

Dexamethasone-induced protein — O95424 (reviewed: O95424)

Alternative names: Protein MYLE

All UniProt accessions (1): O95424

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Highest levels in heart. Also expressed in brain, liver, pancreas, placenta and lung. Up-regulated in emphysematous lung compared to normal lung.

Induction. By dexamethasone.

Similarity. Belongs to the DEXI family.

RefSeq proteins (1): NP_054734* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR023259	Dexamethasone-induced	Family

Pfam: PF15198

UniProt features (1 total): chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95424-F1	69.88	0.21

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 137 (showing top): TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, AAGCAAT_MIR137, MODULE_255, GAANYNYGACNY_UNKNOWN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, MODULE_317, TGACCTY_ERR1_Q2, ROSS_LEUKEMIA_WITH_MLL_FUSIONS, LYF1_01, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, KAAB_FAILED_HEART_VENTRICLE_DN, TGACCTTG_SF1_Q6, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, YAGI_AML_WITH_11Q23_REARRANGED

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

674 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DEXI	CLEC16A	Q2KHT3	805
DEXI	RMI2	Q96E14	674
DEXI	CIITA	P33076	593
DEXI	ZC3H7A	Q8IWR0	588
DEXI	MRPS28	Q9Y2Q9	571
DEXI	RD3L	P0DJH9	507
DEXI	MAP6D1	Q9H9H5	454
DEXI	LRRC1	Q9BTT6	444
DEXI	RFXAP	O00287	440
DEXI	GPR139	Q6DWJ6	433
DEXI	MRPL45	Q9BRJ2	430
DEXI	WIPF2	Q8TF74	427
DEXI	C3orf18	Q9UK00	423
DEXI	RRH	O14718	422
DEXI	SOCS1	O15524	419

IntAct

34 interactions, top by confidence:

A	B	Type	Score
UBQLN1	DEXI	psi-mi:“MI:0915”(physical association)	0.560
BMP10	DEXI	psi-mi:“MI:0915”(physical association)	0.560
DEXI	SGTB	psi-mi:“MI:0915”(physical association)	0.560
DEXI	UBQLN1	psi-mi:“MI:0915”(physical association)	0.560
DEXI	TTMP	psi-mi:“MI:0915”(physical association)	0.560
DEXI	PEX16	psi-mi:“MI:0915”(physical association)	0.560
PRKCA	DEXI	psi-mi:“MI:0915”(physical association)	0.560
DEXI	YWHAG	psi-mi:“MI:0915”(physical association)	0.560
DEXI	SETDB1	psi-mi:“MI:0915”(physical association)	0.560
DEXI	KAT5	psi-mi:“MI:0915”(physical association)	0.560
LMO3	DEXI	psi-mi:“MI:0915”(physical association)	0.560
	EBAG9	psi-mi:“MI:0914”(association)	0.350
DEXI	SGTB	psi-mi:“MI:0915”(physical association)	0.000
TTMP	DEXI	psi-mi:“MI:0915”(physical association)	0.000
PEX16	DEXI	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (6): DEXI (Two-hybrid), DEXI (Two-hybrid), DEXI (Two-hybrid), DEXI (Two-hybrid), SGTB (Two-hybrid), DEXI (Affinity Capture-RNA)

ESM2 similar proteins: A8E1G1, B8NI18, F5HEF2, F5HGN8, F5HIC6, O36368, O95424, P03256, P04486, P05729, P06492, P09047, P09301, P0C6J0, P0C6U7, P0C6X6, P0DJX0, P10580, P12418, P12535, P16726, P21698, P22656, P24414, P24635, P25073, P25214, P28938, P28991, P52511, P52512, P68335, P68336, P83978, P89430, Q00028, Q00106, Q00335, Q13323, Q2GF15

Diamond homologs: O95424, Q6AXJ3, Q9WUQ7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

2 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
684953	GRCh37/hg19 16p13.2-13.13(chr16:10196800-11037738)x1	Pathogenic

SpliceAI

402 predictions. Top by Δscore:

Variant	Effect	Δscore
16:10941567:A:AC	donor_gain	1.0000
16:10941567:ACAGG:A	donor_gain	1.0000
16:10941568:C:CC	donor_gain	1.0000
16:10941568:CAGG:C	donor_gain	1.0000
16:10941568:CAGGC:C	donor_gain	1.0000
16:10929555:CAGGT:C	acceptor_gain	0.9900
16:10929560:C:CC	acceptor_gain	0.9900
16:10941340:G:C	donor_gain	0.9900
16:10941355:T:TA	donor_gain	0.9900
16:10941568:CA:C	donor_gain	0.9900
16:10941568:CAG:C	donor_gain	0.9900
16:10941335:A:C	donor_gain	0.9800
16:10941339:A:AC	donor_gain	0.9800
16:10941339:AGT:A	donor_gain	0.9800
16:10941339:AGTCT:A	donor_gain	0.9800
16:10941562:CACTT:C	donor_loss	0.9800
16:10941563:ACTTA:A	donor_loss	0.9800
16:10941564:CTTA:C	donor_loss	0.9800
16:10941565:T:TC	donor_loss	0.9800
16:10941566:T:TG	donor_loss	0.9800
16:10941567:ACAG:A	donor_loss	0.9800
16:10941568:C:CA	donor_loss	0.9800
16:10941596:T:TA	donor_gain	0.9800
16:10941720:A:AC	donor_gain	0.9800
16:10941721:C:CC	donor_gain	0.9800
16:10941734:T:C	donor_gain	0.9700
16:10929557:GGTCT:G	acceptor_gain	0.9600
16:10929558:GT:G	acceptor_gain	0.9600
16:10929559:TC:T	acceptor_loss	0.9600
16:10929560:CTA:C	acceptor_loss	0.9600

AlphaMissense

604 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:10941871:G:C	F45L	0.993
16:10941871:G:T	F45L	0.993
16:10941873:A:G	F45L	0.993
16:10941861:A:G	Y49H	0.988
16:10941895:A:C	N37K	0.988
16:10941895:A:T	N37K	0.988
16:10941832:G:C	F58L	0.986
16:10941832:G:T	F58L	0.986
16:10941834:A:G	F58L	0.986
16:10941847:G:C	N53K	0.986
16:10941847:G:T	N53K	0.986
16:10941869:A:T	L46H	0.986
16:10941857:A:T	I50N	0.984
16:10941869:A:G	L46P	0.984
16:10941872:A:G	F45S	0.983
16:10941912:C:G	G32R	0.982
16:10941854:A:T	V51D	0.978
16:10941843:C:G	G55R	0.977
16:10941875:G:T	A44D	0.977
16:10941851:A:T	L52H	0.975
16:10941899:A:T	V36D	0.975
16:10941806:A:T	L67H	0.974
16:10941890:A:G	L39P	0.974
16:10941863:T:A	E48V	0.973
16:10941882:A:G	Y42H	0.973
16:10941911:C:T	G32D	0.972
16:10941851:A:G	L52P	0.970
16:10941872:A:C	F45C	0.970
16:10941882:A:C	Y42D	0.968
16:10941904:G:C	F34L	0.968

dbSNP variants (sampled 300 via entrez): RS1000227613 (16:10931084 G>T), RS1000281442 (16:10930812 C>T), RS1000380527 (16:10936694 G>C), RS1000438505 (16:10942262 C>A,G,T), RS1000555184 (16:10932273 G>A), RS1000607440 (16:10931955 C>T), RS1000697420 (16:10932229 C>A,T), RS1000778623 (16:10937628 G>T), RS1000856655 (16:10943026 G>A), RS1000961696 (16:10937513 T>C), RS1000965981 (16:10939995 T>G), RS1001127210 (16:10937839 C>T), RS1001349506 (16:10929522 A>C,G,T), RS1001498778 (16:10942893 C>G), RS1001544365 (16:10942688 T>C,G)

Disease associations

OMIM: gene MIM:617901 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST003129_23	Primary biliary cholangitis	2.000000e-14
GCST003184_21	Atopic dermatitis	3.000000e-11
GCST003876_13	Gut microbiota (beta diversity)	5.000000e-08
GCST004866_19	Alopecia areata	2.000000e-07
GCST005212_32	Asthma	3.000000e-10
GCST005536_35	Type 1 diabetes	3.000000e-22
GCST005536_36	Type 1 diabetes	4.000000e-10
GCST006862_9	Asthma	2.000000e-10
GCST007563_26	Allergic disease (asthma, hay fever or eczema)	7.000000e-17
GCST007564_28	Asthma or allergic disease (pleiotropy)	2.000000e-21
GCST008916_12	Asthma	1.000000e-30
GCST009070_4	Eosinophilic esophagitis	1.000000e-07
GCST010090_8	Atopic dermatitis	3.000000e-15

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007874	gut microbiome measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Benzo(a)pyrene	decreases expression, decreases methylation	2
triphenyl phosphate	affects expression	1
alpha-pinene	decreases expression, increases abundance, affects cotreatment	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
ICG 001	increases expression	1
abrine	decreases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases expression, increases response to substance	1
jinfukang	increases expression	1
MT19c compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Leflunomide	decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Air Pollutants	increases abundance, affects cotreatment, decreases expression	1
Cadmium	increases expression	1
Diazinon	increases methylation	1
Doxorubicin	increases expression	1
Ozone	affects cotreatment, decreases expression, increases abundance	1
Smoke	decreases expression	1
Thimerosal	decreases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1
beta-Naphthoflavone	decreases expression	1
Volatile Organic Compounds	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.